xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT05982873</url>
    </required_header>
    <id_info>
      <org_study_id>C24-738</org_study_id>
      <nct_id>NCT05982873</nct_id>
    </id_info>
    <brief_title>Expanded Access to ABBV-400</brief_title>
    <official_title>Expanded Access to ABBV-400</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>AbbVie</agency>
        <agency_class>Industry</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>AbbVie</source>
    <brief_summary>
      <textblock>
        This is an expanded access program (EAP) for eligible participants. This program is designed&#xD;
        to provide access to ABBV-400 prior to approval by the local regulatory agency. Availability&#xD;
        will depend on territory eligibility. A medical doctor must decide whether the potential&#xD;
        benefit outweighs the risk of receiving an investigational therapy based on the individual&#xD;
        patient's medical history and program eligibility criteria.&#xD;
      </textblock>
    </brief_summary>
    <overall_status>Available</overall_status>
    <study_type>Expanded Access</study_type>
    <has_expanded_access>No</has_expanded_access>
    <expanded_access_info>
      <expanded_access_type_individual>Yes</expanded_access_type_individual>
    </expanded_access_info>
    <condition>Non-Small Cell Lung Cancer</condition>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>ABBV-400</intervention_name>
      <description>Intravenous (IV) Infusion</description>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
          - The participant must not be eligible for an ABBV-400 clinical trial.&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>N/A</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>ABBVIE INC.</last_name>
      <role>Study Director</role>
      <affiliation>AbbVie</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>ABBVIE CALL CENTER</last_name>
      <phone>844-663-3742</phone>
      <email>abbvieclinicaltrials@abbvie.com</email>
    </overall_contact>
    <link>
      <url>https://www.abbvieclinicaltrials.com/study/?id=C24-738</url>
      <description>Related Info</description>
    </link>
    <verification_date>August 2023</verification_date>
    <study_first_submitted>August 1, 2023</study_first_submitted>
    <study_first_submitted_qc>August 1, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 9, 2023</study_first_posted>
    <last_update_submitted>August 1, 2023</last_update_submitted>
    <last_update_submitted_qc>August 1, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 9, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <keyword>Expanded Access</keyword>
    <keyword>Pre-approval Access</keyword>
    <keyword>Compassionate Use</keyword>
    <keyword>Special Access Program</keyword>
    <keyword>Named Patient Basis</keyword>
    <keyword>Special Access Scheme</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    </condition_browse>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT05982873
  org study id: C24-738
  nct id: NCT05982873
  lead sponsor: 
  This is an expanded access program (EAP) for eligible participants. This program is designed
        to provide access to ABBV-400 prior to approval by the local regulatory agency. Availability
        will depend on territory eligibility. A medical doctor must decide whether the potential
        benefit outweighs the risk of receiving an investigational therapy based on the individual
        patient's medical history and program eligibility criteria.
  expanded access type individual: Yes
  intervention type: Drug
  intervention name: ABBV-400
  description: Intravenous (IV) Infusion
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: N/A
  healthy volunteers: No
  last name: ABBVIE INC.
  role: Study Director
  affiliation: AbbVie
  last name: ABBVIE CALL CENTER
  phone: 844-663-3742
  email: abbvieclinicaltrials@abbvie.com
  url: https://www.abbvieclinicaltrials.com/study/?id=C24-738
  description: Related Info
  responsible party type: Sponsor
  mesh term: Carcinoma, Non-Small-Cell Lung